Establishment Labs clears 28 implant sizes. Establishment Labs stock falls 4.26 percent

Published on 10/08/2026 at 20:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 67.54 million, up 31.70 percent year over year. Establishment Labs stock cost EUR 54.60 on October 8, 2026 versus EUR 57.03.

Key points in brief

Establishment Labs reported FDA clearance for 28 additional Motiva implant sizes in the United States on October 8, 2026.
Second-quarter 2026 revenue rose 31.70 percent year over year to USD 67.54 million.
Establishment Labs stock stood at EUR 54.60 at Lang & Schwarz on October 8, 2026, down 4.26 percent versus EUR 57.03.

ESTA, VGG312491084, Illustration mit AI erstellt.

Establishment Labs Holdings Inc. received U.S. clearance for 28 additional Motiva SmoothSilk Round and Ergonomix breast implant sizes on October 8, 2026, extending the portfolio to sizes as small as 105 cc. Simply Wall St reported that the clearance covers Mini, Demi and Full profiles, giving surgeons more combinations for aesthetic and reconstructive procedures.

Three milestones show the growth path

On May 6, 2026, first-quarter revenue reached USD 59.88 million, up 45.00 percent from the prior-year quarter, according to Simply Wall St. The company then reported second-quarter revenue of USD 67.54 million on August 6, 2026, representing 31.70 percent year-over-year growth.

Benzinga reported that adjusted EBITDA reached USD 3.70 million in the second quarter of 2026, compared with a USD 8.50 million loss in the prior-year quarter. The quarter also ended with USD 71.20 million in cash and cash equivalents, while operating expenses included USD 2.20 million of one-time restructuring and debt-refinancing charges.

What does 28 sizes change for growth?

The broader U.S. product menu gives Establishment Labs more options to address smaller-framed patients and revision or reconstruction cases. The commercial test is conversion into procedures and surgeon adoption, not the clearance count alone; the company is also expanding its minimally invasive platform, which generated USD 12.10 million of second-quarter revenue.

The U.S. accounted for USD 24.70 million of second-quarter revenue, up 140.90 percent from the prior-year quarter, while revenue outside the United States reached USD 42.80 million, up 4.40 percent. That split makes U.S. execution the larger near-term growth lever, while international sales provide diversification.

Analyst target remains above the market

Canaccord Genuity analyst Caitlin Roberts reiterated a Buy rating and set a USD 105.00 price target on October 6, 2026, according to Markets Insider. The same report cited a USD 103.00 target from BTIG. Both targets are in U.S. dollars and are separate from the euro quotation used for German investors.

Recent reporting dates and stock

The substantiated reporting dates are May 6, 2026 for first-quarter results and August 6, 2026 for second-quarter results. The October 8 product clearance adds a regulatory milestone to the 2026 growth record.

Establishment Labs stock was trading at EUR 54.60 at Lang & Schwarz on October 8, 2026 at 8:40 p.m. CEST, down 4.26 percent versus the prior close of EUR 57.03 on October 7, 2026. The primary listing is Nasdaq, where the finance quote showed USD 61.11 at 6:46 p.m. UTC on October 8, 2026; the 52-week range was USD 38.38 to USD 97.59 and market capitalization was USD 1.8 billion.

The further course of trading is shown by the continuously updated real-time quote of Establishment Labs stock.